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Background. Early identification of patients with chronic viral hepatitis coinfected with human immunodeficiency virus (HIV) 
is essential for optimal care. The objectives of this study were to estimate the prevalence of HIV coinfection among patients newly 
diagnosed with chronic viral hepatitis, HIV testing prevalence, and identify factors associated with coinfection.
Methods. Patients with chronic viral hepatitis newly enrolled in The Danish Database for Hepatitis B and C between 2002 and 
2015 were identified. The HIV coinfection prevalence was calculated, and risk factors associated with HIV coinfection were esti-
mated by logistic regression.
Results. In total, 8490 patients were included: 3091 had chronic hepatitis B (CHB), 5305 had chronic hepatitis C (CHC), and 
94 had CHB and CHC. The prevalence of HIV coinfection was 4.4% (95% confidence interval [CI], 4.0–4.9) and was higher among 
CHC and CHB-CHC patients than CHB patients with a prevalence of 5.3% (95% CI, 4.7–5.9), 6.4% (95% CI, 2.4–13.4), and 2.9 
(95% CI, 2.3–3.5), respectively (P < .0001). The HIV testing prevalence increased from 65% to 88% between 2002 and 2014 concur-
rently with a decrease in the HIV coinfection prevalence from 7.8% (95% CI, 5.5–10.7) to 1.6% (95% CI, 0.7–3.2). Age 35–50 years, 
male sex, and sexual route of viral hepatitis transmission were associated with HIV coinfection with odds ratios of 4.42 (95% CI, 
1.40–13.94), 2.21 (95% CI, 1.74–2.81), and 8.81 (95% CI, 6.30–12.33), respectively.
Conclusions. The prevalence of HIV coinfection among patients with newly diagnosed chronic viral hepatitis decreased concur-
rently with an increase in HIV testing prevalence.
Keywords. chronic viral hepatitis; HIV; nationwide cohort study; prevalence.
 
Human immunodeficiency virus (HIV), hepatitis B virus 
(HBV), and hepatitis C virus (HCV) are all blood-borne 
pathogens and thus share routes of transmission, such as sex-
ual contact, from mother to child during pregnancy (verti-
cal), intravenous drug use (IDU), or blood transfusion [1–3]. 
Consequently, a small but significant population of coinfected 
patients with HIV and chronic viral hepatitis exists [4, 5]. It 
has long been known that patients with HBV or HCV and HIV 
coinfection have a more rapidly progressing course of liver 
disease [6–12] and increased risk of chronic kidney disease 
[13]. In addition, early initiation of highly active antiretro-
viral therapy (HAART) is essential to avoid serious acquired 
immune deficiency syndrome (AIDS)-related events among 
HIV-infected individuals [14]. As a result, early identifica-
tion of patients with HIV coinfection among patients with 
viral hepatitis is crucial. In line with international guidelines, 
the Danish clinical practice guidelines recommend that all 
patients newly diagnosed with chronic hepatitis B (CHB) and/
or chronic hepatitis C (CHC) are tested for HIV [2, 15, 16]. 
Since the Danish clinical practice CHB and CHC guidelines 
were introduced, a great effort has been made to increase HIV 
testing of chronic viral hepatitis patients [15, 17].
Denmark is a low-prevalence country with regards to HIV, 
CHB, and CHC with estimated prevalences of approximately 
0.2% [18], 0.2% [19], and 0.4% [20], respectively. A previously 
published Danish regional study suggested an HIV coinfection 
prevalence of 5% among patients with CHC [21]. However, 
no peer-reviewed, nationwide studies on Danish patients have 
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been published with regards to the HIV prevalence among 
chronic viral hepatitis patients.
Previous studies have primarily focused on viral hepatitis 
coinfection among patients infected with HIV, and nation-
wide information is lacking on the HIV coinfection prevalence 
among patients with chronic viral hepatitis and risk factors 
associated with HIV coinfection.
Therefore, in this nationwide cohort study, we aimed to esti-
mate the prevalence of HIV coinfection among patients newly 
diagnosed with CHB and CHC in Denmark and to describe 
changes in the HIV testing prevalence and prevalence of HIV 
coinfection over time. Moreover, we wished to investigate 
whether any baseline characteristics of patients newly diagnosed 
with CHB and/or CHC were associated with HIV coinfection.
MATERIALS AND METHOD
Setting
All citizens in Denmark are provided with a unique, 10-digit 
person identification number that permits linkage between 
multiple data sources. Healthcare services are publicly funded 
and free of charge to the individual in Denmark. The prospec-
tively collected data used in this nationwide cohort study were 
extracted from The Danish Database for Hepatitis B and C 
(DANHEP). The DANHEP is a nationwide database, initiated 
on January 1, 2002, with ongoing enrollment of all patients over 
the age of 15 years attending specialized care for CHB and/or 
CHC in Denmark. Currently, all 18 hospital departments of 
either infectious diseases, internal medicine with infectious dis-
eases specialists, or gastroenterology are responsible for care of 
patients with CHB and CHC contribute to DANHEP. The data-
base contains data on patient demographics and clinical and 
laboratory results.
Study Population
Data from DANHEP were extracted in July 2015. Chronic 
hepatitis B was defined as a positive hepatitis B surface anti-
gen (HBsAg) before or at least 6  months after enrollment in 
DANHEP. Chronic hepatitis C was defined as the detection of 
HCV-ribonucleic acid (RNA) before or within 6 months after 
enrollment in DANHEP. Chronic infection with HBV and HCV 
(CHB-CHC) was defined as fulfilling the criteria for both CHB 
and CHC. All patients enrolled in DANHEP after January 1, 
2002 who met the criteria for CHB and/or CHC and who were 
at least 15 years of age were included in this study. At the date 
of enrollment in DANHEP, the patient was considered newly 
diagnosed with chronic viral hepatitis.
We extracted results of HIV antibody/antigen tests per-
formed before or within 6 months of enrollment in DANHEP 
with viral hepatitis (HIV positive, HIV negative, or unknown 
HIV status [Supplementary Material]). An HIV test performed 
at any point before July 2015, regardless of its relation to enroll-
ment in DANHEP, was defined as “ever HIV tested”.
In the presence of conflicting results with regards to HCV-
RNA, HBsAg, and HIV antigen/antibody test results registered 
in DANHEP at enrollment, an ad hoc assessment in each case 
was performed to determine the hepatitis and HIV status. All 
laboratory analyses were performed locally at the hospital 
responsible for care of the patient.
Definition of Covariates
We categorized the following patient characteristic covariates 
at enrollment:
• Country of birth (Western Europe [including Greenland], 
Eastern Europe, Africa, Asia, North America, South America, 
and other)
• Alcohol abuse was defined as the self-reported weekly con-
sumption of more than 14 units of alcohol for women and 21 
units of alcohol for men.
• Route of transmission was defined as self-reported suspected 
route of viral hepatitis transmission (IDU, tattoo/piercing, 
vertical transmission, sexual transmission, blood/blood 
product exposure [including needle injury], multiple, and 
other reasons).
• Reason for testing for viral hepatitis (clinical symptoms 
[including elevated liver function tests]; screening during 
pregnancy; screening for other reasons [including screening 
of persons with known risk factors defined by the Danish 
Health and Medicines Authorities {Supplementary Material}] 
[15]; and other reasons)
• Sex (male, female)
• Age at enrollment
• Clinical cirrhosis (yes/no) was defined as the presence of 
clinical signs of cirrhosis before or up to 6 months after the 
enrollment date (oesophageal varices, ascites, and hepatic 
encephalopathy).
• HCV genotype
Statistical Analyses
Baseline characteristics are presented as median with interquar-
tile range or absolute and relative frequencies. Differences in 
patient characteristics between hepatitis groups (CHB, CHC, 
and CHB-CHC) were tested for statistical significance by apply-
ing the Kruskal-Wallis, Fisher’s exact test, χ2, or χ2 test with 
Montecarlo simulation using 10 000 samples, whenever appro-
priate. The prevalence of HIV coinfection with 95% confidence 
interval (CI) was calculated using the Clopper-Pearson [22] 
exact method as the number of HIV-positive individuals divided 
by the total number of patients including patients with unknown 
HIV status. To estimate the risk of HIV coinfection (HIV pos-
itive vs HIV nonpositive) associated with different hepatitis 
groups, univariate logistic regression was applied. To estimate 
the change in HIV coinfection prevalence over time between 
2002 and 2015, we used multiple logistic regression analysis with 
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year of enrollment in DANHEP as a continuous covariate and 
adjusted for sex, age, and country of birth. Year of enrollment 
and age were tested for log linearity, and because age did not 
show log linearity it was introduced as a categorical covariate. 
To estimate the risk of HIV coinfection associated with sex, age, 
and country of birth (Western Europe as reference), we used 
univariate logistic regression models. The risk of HIV coinfec-
tion associated with route of transmission was estimated using 
multiple logistic regression models adjusting for confounding 
factors. Further details on the handling of the substantial num-
ber of missing values for route of transmission can be found in 
the Supplementary Material. All logistic regression models were 
determined on the basis of directed acyclic graphs [23] to reduce 
bias (Supplementary Figure 1). Human immunodeficiency virus 
testing and HIV coinfection prevalence were compared between 
departments of gastroenterology and hepatology versus depart-
ments with infectious diseases specialists using the χ2 test.
Multiple logistic regression models were tested for goodness-
of-fit by applying the Hosmer-Lemeshow test [24]. Statistical tests 
were 2-sided, and P < .05 was considered statistically significant. 
All statistical analyses were performed using SAS 9.4 (SAS Institute 
Inc., Cary, NC), and figures were created using R studio [25].
Ethical Approval
This study was approved by the Danish Data Protection agency 
in accordance with Danish law (J.nr. 2012-58-0023).
RESULTS
Study Population
As of July 2015, 10 784 patients had been enrolled in DANHEP. 
We excluded 2294 patients in total, 1715 of whom patients 
were enrolled before January 1, 2002, 517 patients did not ful-
fill the definitions of either CHB or CHC, and 62 patients were 
<15 years. Of the 8490 patients included, 3091 had CHB, 5305 
had CHC, and 94 had both CHB and CHC. Baseline charac-
teristics stratified by hepatitis group are presented in Table 1. 
Patients with CHB were younger than CHC and CHB-CHC 
patients, and the distribution of sex differed between the hep-
atitis groups with more female CHB patients than CHC and 
CHB-CHC patients. The overall prevalence of HIV was 4.4% 
(95% CI, 4.0–4.9), and the prevalence was 2.9% (95% CI, 
2.3–3.5) among CHB patients, 5.3% (95% CI, 4.7–5.9) among 
CHC patients, and 6.4% (95% CI, 2.4–13.4) among CHB-CHC 
patients (P < .0001).
Human Immunodeficiency Virus-Coinfected Patients
Baseline characteristics of patients with HIV coinfection can 
be seen in Table  2 and Supplementary Table  1. The majority 
of HIV-coinfected patients had CHC (75%), and their demo-
graphic characteristics were akin to that of the CHC popula-
tion with regards to the distribution of sex and country of 
birth. Sexual route of viral hepatitis transmission was more 
prevalent among HIV-positive patients (22.1% vs 2.7%), 
and vertical transmission of viral hepatitis was rare in HIV-
coinfected patients (0.8% vs 9.8%).
Human Immunodeficiency Virus Testing
In the entire study population, 79.6% were tested for HIV as 
newly diagnosed with viral hepatitis at enrollment in DANEHP 
and 87.8% of patients were ever tested for HIV coinfection 
before July 2015. In addition to HIV-positive patients identi-
fied at enrollment in DANHEP, an additional 20 patients were 
diagnosed with HIV coinfection a median of 44 months (range, 
9–116) after enrollment. Seven of these 20 patients were not 
HIV tested at enrollment and had their first positive HIV test 
performed a median of 41  months after enrollment (range, 
9–116). The remaining 13 patients were HIV negative at enroll-
ment in DANHEP and subsequently became HIV positive after 
a median of 47 months (range, 11–101).
The HIV testing prevalence among newly diagnosed chronic 
viral hepatitis patients increased from 64.5% in 2002 to 87.7% 
in 2014, respectively, whereas the prevalence of HIV coinfection 
among newly enrolled patients during the same period fell from 
7.8% (95% CI, 5.5–10.7) in 2002 to 1.6% (95% CI, 0.7–3.2) in 
2014. Human immunodeficiency virus coinfection status (posi-
tive, negative, unknown) for all patients, CHB and CHC patients, 
in relative and absolute frequencies, for each year of enrollment 
between 2002 and 2014 (the last year with complete data), are 
shown in Figure 1A–C and Supplementary Figure 2A–C, respec-
tively. Departments of gastroenterology and hepatology were less 
likely to test for HIV than departments with infectious disease 
specialists (70.4% vs 82.8%, P < .0001) (Supplementary Table 2).
Patient Characteristics Associated With Human Immunodeficiency Virus 
Coinfection
We found that CHC was associated with HIV coinfection with 
an odds ratio (OR) of 1.89 (95% CI, 1.48–2.41) compared with 
CHB patients. After adjusting for sex, age and country of birth, 
we found that the prevalence of HIV coinfection decreased over 
time between 2002 and 2015 with an OR of HIV coinfection 
of 0.84 (95% CI, 0.82–0.87) per year. Estimates of OR for HIV 
coinfection associated with baseline characteristics are listed in 
Table  3. We found that age 35–50  years (OR  =  4.42; 95% CI, 
1.40–13.94), male sex (OR  =  2.21; 95% CI, 1.74–2.81), birth 
in South America (OR = 3.62; 95% CI, 1.67–7.86), and sexual 
transmission of viral hepatitis (OR = 8.81; 95% CI, 6.30–12.33) 
were associated with HIV coinfection. We were surpised to 
find that all 8 HIV-coinfected patients from South America 
had CHC, 7 of whom reported sexual route of viral hepatitis 
transmission. Birth in Asia (OR  =  0.31; 95% CI, 0.22–0.44) 
and vertical transmission of viral hepatitis (OR = 0.09; 95% CI, 
0.03–0.29) were negatively associated with HIV coinfection.
DISCUSSION
In this nationwide cohort study of patients with newly diag-
nosed chronic viral hepatitis attending specialized care, we 
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found an overall prevalence of HIV coinfection of 4.4% and an 
increase in HIV testing prevalence coinciding with a decrease in 
the prevalence of HIV coinfection since 2002. Chronic hepatitis 
C or CHB-CHC, younger age, male sex, birth in South America, 
and sexual transmission of viral hepatitis were associated with 
a higher prevalence of HIV coinfection. In contrast, patients of 
Table 1. Baseline Characteristics
Variable Chronic Hepatitis B Chronic Hepatitis C Chronic Hepatitis B and C Totala
Number (%) 3091 (36.4) 5305 (62.5) 94 (1.1) 8490
Age at diagnosis (median, q1, q3) 34.9 (27.6–44.8) 45.0 (36.6–52.4) 41.3 (35.0–49.2) 41.4 (32.4–50.5),
P < .0001
Women, N (%) 1654 (53.5) 1768 (33.3) 27 (28.7) 3449 (40.6)
P < .0001
HIV status
 Positive 89 (2.9) 281 (5.3) 6 (6.4) 376 (4.4)
 Negative 2198 (71.1) 4119 (77.6) 67 (71.3) 6384 (75.2)
 Unknown 804 (26.0) 905 (17.1) 21 (22.3) 1730 (20.4)
P < .0001b
Origin/country of birth 450 (14.6) 129 (2.4) 4 (4.3) 583 (6.9)
Africa 1592 (51.5) 409 (7.7) 20 (21.3) 2021 (23.8)
Asia 285 (9.2) 262 (4.9) 4 (4.3) 551 (6.5)
Eastern Europe 2 (0.1) 21 (0.4) - 23 (0.3)
North America 13 (0.4) 32 (0.6) - 45 (0.5)
South America 509 (16.5) 4279 (80.7) 61 (64.9) 4849 (57.1)
Western Europec 47 (1.5) 16 (0.3) - 63 (0.7)
Otherd 193 (6.2) 157 (3.0) 5 (5.3) 355 (4.2)
Unknown P < .0001
Route of transmission 61 (2.0) 268 (5.1) - 329 (3.9)
Blood/blood product exposuree 67 (2.2) 3238 (61.0) 53 (56.4) 3358 (39.6)
IDU 126 (4.1) 164 (3.1) 1 (1.1) 291 (3.4)
Sexual contact 14 (0.5) 107 (2.0) 2 (2.1) 123 (1.5)
Tattoo/piercing 886 (28.7) 25 (0.5) 7 (7.5) 918 (10.8)
Vertical - 13 (0.3) - 13 (0.2)
Multiple 74 (2.4) 70 (1.3) 4 (4.3) 148 (1.7)
Other reason 1863 (60.3) 1420 (26.8) 27 (28.7) 3310 (39.0)
Unknown P < .0001
Diagnostic test reason 544 (17.6) 1585 (29.9) 28 (29.8) 2157 (25.4)
Clinical symptoms 372 (12.0) 590 (11.1) 13 (13.8) 975 (11.5)
Other reason 450 (14.6) 52 (1.0) 1 (1.1) 503 (5.9)
Screening pregnancy 1063 (34.4) 1624 (30.6) 20 (21.3) 2707 (31.9)
Screening other 662 (21.4) 1454 (27.4) 32 (34.0) 2148 (25.3)
Unknown P < .0001
History of alcohol abuse 128 (4.1) 1348 (25.4) 17 (18.1) 1493 (17.6)
P < .0001
HCV genotype
 Genotype 1 - 2086 (39.3) 33 (35.1) 2119 (39.3)
 Genotype 2 - 388 (7.3) 4 (4.3) 392 (7.3)
 Genotype 3 - 2049 (38.6) 25 (26.6) 2074 (38.4)
 Genotype 4–6 - 140 (2.6) 2 (2.1) 142 (2.6)
 Multiple genotypes - 54 (1.0) 2 (2.1) 56 (1.0)
 Unknown - 588 (11.1) 28 (29.8) 616 (11.4)
P = .49
Clinical cirrhosis 31 (1.0) 219 (4.1) 2 (2.1) 252 (3.0)
P < .0001
Abbreviations: HIV, human immunodeficiency virus; IDU, intravenous drug use.
aKruskal-Wallis, Fisher’s exact, χ2 test, or χ2 test with Montecarlo simulation using 10 000 samples when appropriate. 
bHIV positive vs not HIV positive.
cIncluding Greenland.
dIncluding Australia, New Zealand, and Pacific Islands.
eIncluding needle stick injuries.
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Asian origin and patients vertically infected with viral hepatitis 
showed a lower prevalence HIV coinfection.
The prevalence of HIV coinfection among CHB patients 
found in our study is slightly lower than the estimates pub-
lished from other low HIV-prevalence settings (United States) 
of 5.2%–6.3% among CHB patients [26, 27], whereas the over-
all HIV coinfection prevalence of 5.3% among CHC patients 
found in our study was similar to estimates found in larger CHC 
patient cohorts from the United Kingdom (UK) and the United 
States at 5.0% and 4.3%, respectively [27, 28].
Demographics of CHB patients in our study differed from 
CHB patients in the US-based studies [26, 27] with fewer from 
Asia, fewer women, and more were sexually infected with HIV, 
whereas the demographic characteristics of CHC patients in 
our study were similar to patients with CHC included in the 
UK study [28]. However, no previous nationwide study has 
Table 2. Patient Characteristics of HIV-Positive Patients, HIV-Negative Patients, and Patients With Unknown HIV Status
Patient Characteristic HIV Positive HIV Negative HIV Unknown P Valuea
Number 376 6384 1730
Age, median (IQR) 40.3 (34.7–47.7) 41.4 (32.5–50.5) 41.9 (31.4–51.3) .8
Women, N (%) 91 (24.2) 2550 (40.0) 808 (46.7) <.0001
Hepatitis type
Hepatitis B 89 (23.7) 2198 (34.4) 804 (46.5) <.0001
Hepatitis C 281 (74.7) 4119 (64.5) 905 (52.3)
Hepatitis B and C 6 (1.6) 67 (1.1) 21 (1.2)
Country of Birth, N (%)
Africa 30 (8.0) 431 (6.8) 122 (7.1) <.0001
Asia 37 (9.8) 1484 (23.3) 500 (28.9)
Eastern Europe 19 (5.1) 437 (6.9) 95 (5.5)
North America 1 (0.3) 15 (0.2) 7 (0.4)
South America 8 (2.1) 32 (0.5) 5 (0.3)
Western Europeb 273 (72.6) 3728 (58.4) 848 (49.0)
Otherc 3 (0.8) 39 (0.6) 21 (1.2)
Unknown 5 (1.3) 218 (3.4) 132 (7.6)
Route of Transmission, N (%)
Blood/blood product exposured 11 (2.9) 235 (3.7) 83 (4.8) <.0001
IDU 166 (44.2) 2708 (42.4) 484 (28.0)
Sexual contact 83 (22.1) 172 (2.7) 36 (2.1)
Tattoo/piercing 2 (0.5) 96 (1.5) 25 (1.5)
Vertical 3 (0.8) 625 (9.8) 290 (16.8)
Multiple 0 (-) 11 (0.2) 2 (0.1)
Other Reason 2 (0.5) 112 (1.8) 34 (2.0)
Unknown 109 (29.0) 2425 (38.0) 776 (44.9)
Diagnostic Test Reason, N (%)
Clinical symptoms 77 (20.5) 1565 (24.5) 515 (29.8) <.0001
Other reason 34 (9.0) 773 (12.1) 168 (9.7)
Screening pregnancy 2 (0.5) 402 (6.3) 99 (5.7)
Screening other 137 (36.4) 2025 (31.7) 545 (31.5)
Unknown 126 (33.5) 1619 (25.4) 403 (23.3)
History of alcohol abuse, N (%) 45 (12.0) 1205 (18.9) 243 (14.1) <.0001
HCV Genotype, N (%)e
Genotype 1 133 (46.3) 1626 (38.8) 360 (38.9) <.0001
Genotype 2 17 (5.9) 290 (6.9) 85 (9.2)
Genotype 3 81 (28.2) 1670 (39.9) 323 (34.9)
Genotype 4–6 22 (7.7) 89 (2.1) 31 (3.4)
Multiple genotypes 5 (1.7) 41 (1.0) 10 (1.1)
Unknown 29 (10.1) 470 (11.2) 117 (12.6)
Clinical cirrhosis, N (%) 5 (1.3) 196 (3.1) 51 (3.0) .15
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, intravenous drug use; IQR, interquartile range.
aKruskal-Wallis, χ2 test, or χ2 test with Montecarlo simulation using 10 000 samples when appropriate.
bIncluding Greenland.
cIncluding Australia, New Zealand, and Pacific Islands.
 dIncluding needle stick injuries. 
eGenotype distribution among patients with chronic hepatitis C.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/5/12/ofy310/5195492 by R
oyal Library C
openhagen U
niversity user on 17 April 2019
6 • OFID • Hallager et al
been conducted, and a systematic review found considerable 
variation in the prevalence of HIV coinfection among European 
patients with CHC living with intravenous drug use, ranging 
from 0% to 70% [29]. The low HIV prevalence in the Danish 
population [18], the nationwide design with inclusion of viral 
hepatitis patients from various risk groups, may partly explain 
differences between the HIV coinfection prevalence found in 
the Danish viral hepatitis population and those described else-
where [26, 30, 31]. Moreover, the universal access to healthcare 
services and drug addiction treatment with needle exchange 
programs (all free of charge) in Denmark [32] may be partly 
responsible.
Although we have no data to draw any definitive conclu-
sions as to why the HIV coinfection prevalence is declining in 
the Danish chronic viral hepatitis population, one could spec-
ulate that access to HAART (which reduces sexual HIV trans-
mission [33]), needle exchange programs, and/or oral opioid 
substitution therapy of intravenous drug users may play a 
role. Our data showed a steady increase in the proportion of 
patients tested for HIV throughout the study period, which 
is most likely the result of a national effort to increase HIV 
testing in risk groups [15], the process of making HIV testing 
routine in all patients newly diagnosed with chronic viral 
hepatitis, and the introduction of screening for HIV in preg-
nant women. The importance of knowledge about HIV by the 
physician may be indicated by the fact that patients attending 
departments of infectious diseases appeared to be more likely 
to be tested for HIV than patients attending departments of 
gastroenterology.
Approximately 60% of the Danish CHC cohort is infected 
with HCV through IDU, and the majority are males and infected 
in Denmark [20, 34]. In contrast, the population of CHB 
patients in Denmark comprises primarily relatively younger 
women, many of whom were vertically infected with HBV in 
their country of origin, often Asia, Africa, and the Middle East 
[35]. Immigration, and the introduction of nationwide screen-
ing of pregnant women for HBV in 2005 and HIV infection 
in 2010 in Denmark [36, 37], may have influenced the demo-
graphics of the chronic viral hepatitis cohort and their HIV 
coinfection prevalence because the prevalence of HIV infection 
is very low among pregnant women in Denmark (0.06% HIV 
infected among all pregnant women tested in 2016 [38]). Only 
1 of 203 (0.5%) HBsAg-positive pregnant women were also 
HIV positive (M. Wessman, written personal communication, 
15 December 2017). The majority of individuals infected with 
HIV in Denmark are male, with a median age of 34  years at 
Table 3. Risk Factors Associated With HIV Coinfection Among Patients 
With Newly Diagnosed Chronic Viral Hepatitis B and/or C
Risk Factor
Odds Ratio  
(95% CI) N
Patients with CHC vs CHBa 1.89 (1.48–2.41) 8490
Patients with CHB-CHC vs CHBa 2.3 (0.98–5.40) 8490
Ageb, years
≤35 2.64 (0.83–8.39) 8490
>35–≤50 4.42 (1.40–13.94)
>50–≤65 2.41 (0.75–7.73)
>65 Reference
Sex, men vs womenc 2.21 [1.74; 2.81] 8490
Year of enrollmentd 0.84 [0.82; 0.87] 8135
Country of birth, Africa vs WEe 0.91 [0.62; 1.34] 8135
Country of birth, Asia vs WEe 0.31 [0.22; 0.44] 8135
Country of birth, Eastern Europe vs WEe 0.60 [0.37; 0.96] 8135
Country of birth, North America vs WEe 0.76 [0.10; 5.67] 8135
Country of birth, South America vs WEe 3.62 [1.67; 7.86] 8135
Route of transmission, blood exposure vs IDUf 0.67 [0.34; 1.29] 5023
Route of transmission, sexual transmission vs IDUf 8.81 [6.30; 12.33] 5023
Route of transmission, tattoo/piercing vs IDUf 0.30 [0.07; 1.26] 5023
Route of transmission, vertical transmission vs IDUf 0.09 [0.03; 0.29] 5023
Abbreviations: CHB, chronic hepatitis B virus; CHC, chronic hepatitis C virus; CI, confidence 
interval; IDU, intravenous drug use; OR, odds ratio; WE, Western Europe.
 aUnivariate, type 3 test (P < .0001).
bUnivariate, type 3 test (P < .0001).
cUnivariate.
dAdjusted for sex, age, and country of birth.
eUnivariate, type 3 test (P < .0001). 
fAdjusted for age, sex, year of enrollment, country of birth, type 3 (P < .0001).
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Figure 1. Human immunodeficiency virus (HIV)-status in percentage among all 
newly diagnosed patients with chronic viral hepatitis between 2002 and 2014. (A) 
All patients. (B) Patients with chronic hepatitis B virus (HBV) infection. (C) Patients 
with chronic hepatitis C virus (HCV) infection.
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HIV diagnosis, approximately half of whom have been infected 
through homosexual transmission, and only approximately 10% 
are infected through IDU [39, 40]. Hence, it was not surprising 
to find that younger age, male sex, and sexual transmission of 
viral hepatitis were associated with a higher prevalence of HIV 
coinfection and that Asian origin and vertical transmission were 
associated with a lower HIV coinfection prevalence. The higher 
risk of HIV coinfection associated with HCV seen in this study 
is presumed to be due to underlying differences in behavioral 
risks (eg, IDU, men who have sex with men [MSM] [41]) and 
not due to a causal link between HCV and HIV per se. However, 
our data limit further conclusions on whether sexual transmis-
sion was in fact more likely to be among MSM or sex workers. 
A more surprising finding was the association between South 
American origin and HIV coinfection. Our study included very 
few patients from South America with a surprisingly high HIV 
coinfection prevalence among CHC patients—approximately 
all of whom had been sexually infected with HCV. The HIV 
epidemic in South and Central America varies, but in many 
countries it is driven by transmission among MSM [42], with a 
median HCV seroprevalence of 11% among people living with 
HIV/AIDS, with considerable variation throughout the region 
[43]. Thus, the association could represent a selected group of 
South American patients with high-risk behavior but is most 
likely the result of a spurious finding.
A major strength of our study is the nationwide design 
with comprehensive data. However, the fact that Denmark is 
a low-prevalence country with regards to HBV, HCV, and HIV 
limits the generalizability to other settings. Despite the nation-
wide design, DANHEP only includes patients with CHB or 
CHC attending specialized care. There are a substantial num-
ber of patients in Denmark with either undiagnosed chronic 
viral hepatitis or diagnosed viral hepatitis but not enrolled 
in specialized care [19, 20]. In addition, DANHEP does not 
include detailed information on homosexual and heterosexual 
behavior or sex work, and a large proportion of patients had 
unknown route of transmission. Whether this is due to gen-
uine ignorance about the route of transmission or an unwill-
ingness to reveal behavioral risks (such as MSM, sex work, or 
IDU) is unknown.
Because HIV, HBV, and HCV are blood-borne viruses and 
share routes of transmission, patients diagnosed with viral hep-
atitis have at least 1 risk factor for HIV coinfection (ie, IDU, ver-
tical transmission etc). An HIV test is cheap, easy to perform, 
and associated with negligible health risks, and because the 
consequences of missing an HIV diagnosis can have detrimen-
tal consequences, we strongly recommend HIV testing all viral 
hepatitis patients regardless of their risk profile. Our results also 
indicate that there is still room for improvement in HIV testing 
among chronic viral hepatitis patients in Denmark, but a con-
tinuous focus on this area may well lead to improvements in 
HIV testing frequencies.
CONCLUSIONS
In conclusion, in this nationwide study including patients with 
newly diagnosed chronic viral hepatitis, the prevalence of HIV 
coinfection in Denmark decreased between 2002 and 2014 con-
currently with an observed increase in HIV testing prevalence. 
The overall prevalence of HIV coinfection was approximately 
4%, but it was higher among patients with CHC and CHB-CHC 
coinfection than patients with CHB and higher among patients 
of male sex, younger age, and with sexual transmission of viral 
hepatitis.
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